Oculis Holding AG (NASDAQ:OCS) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Oculis Holding AG (NASDAQ:OCS) has been given an average recommendation of “Moderate Buy” by the nine ratings firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $43.50.

A number of brokerages have issued reports on OCS. JPMorgan Chase & Co. started coverage on shares of Oculis in a report on Friday, December 19th. They issued an “overweight” rating and a $38.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Oculis in a research report on Thursday, January 22nd. Wall Street Zen downgraded shares of Oculis from a “hold” rating to a “sell” rating in a report on Saturday. HC Wainwright increased their target price on shares of Oculis from $42.00 to $44.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Finally, Bank of America decreased their target price on Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a research report on Thursday, November 13th.

Institutional Investors Weigh In On Oculis

Institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE grew its holdings in shares of Oculis by 2.2% in the 2nd quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock worth $786,000 after purchasing an additional 878 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Oculis by 100.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock worth $40,000 after buying an additional 1,000 shares during the last quarter. Aventura Private Wealth LLC acquired a new stake in shares of Oculis during the fourth quarter worth approximately $80,000. Geode Capital Management LLC increased its holdings in shares of Oculis by 27.7% during the second quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock worth $571,000 after buying an additional 6,384 shares in the last quarter. Finally, Compagnie Lombard Odier SCmA raised its stake in shares of Oculis by 10.6% in the fourth quarter. Compagnie Lombard Odier SCmA now owns 107,300 shares of the company’s stock valued at $2,143,000 after acquiring an additional 10,300 shares during the last quarter. 22.30% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Oculis

Here are the key news stories impacting Oculis this week:

• Positive Sentiment: Company is actively presenting at multiple investor conferences in March and reiterated late‑stage pipeline milestones — Privosegtor received breakthrough therapy designation (optic neuritis), OCS‑01 topline readout expected in Q2 2026, and Licaminlimab advancing as a genotype‑driven program — supporting longer‑term upside for the stock. Oculis to Participate in Upcoming Investor Conferences
• Positive Sentiment: HC Wainwright raised a price target to $44 (published by AmericanBankingNews), which can provide technical/psychological support despite other model reductions. HC Wainwright Boosts Oculis Price Target
• Neutral Sentiment: Oculis filed its audited 2025 consolidated financial statements and MD&A on Form 20‑F — useful for diligence but largely informational unless the filings reveal unexpected surprises. Oculis Publishes 2025 Consolidated Financial Statements
• Neutral Sentiment: Company published notifications that RSUs granted to directors have vested and been settled — standard disclosure; could be neutral if shares are retained, or slightly negative if it leads to insider selling. Oculis Publishes Notifications of Transactions
• Negative Sentiment: Multiple analyst teams (LifeSci Capital and HC Wainwright) cut near‑term quarterly and FY2026 EPS forecasts, trimming expectations for Q1–Q4 and lowering FY numbers — these downward revisions increase near‑term earnings uncertainty and likely triggered selling pressure. (Analyst notes summarized on MarketBeat.) Analyst Estimate Reductions

Oculis Trading Down 2.8%

Shares of OCS opened at $26.96 on Monday. Oculis has a 1-year low of $14.00 and a 1-year high of $30.68. The business’s 50-day moving average price is $26.16 and its 200 day moving average price is $21.60. The stock has a market capitalization of $1.56 billion, a P/E ratio of -11.88 and a beta of 0.29. The company has a current ratio of 5.96, a quick ratio of 5.96 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.08). Oculis had a negative net margin of 8,173.41% and a negative return on equity of 62.12%. The business had revenue of $0.50 million for the quarter, compared to analyst estimates of $0.14 million. Analysts expect that Oculis will post -2.09 earnings per share for the current year.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.